K5t7S

257. Seguí J, Lopez-Munoz F, Alamo C, Camarasa X, Garcia-Garcia P, Pardo A. Effects of adjunctive
reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study. J
Psychopharmacol. 2010;24(8):1201-7.
258. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al.
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder:
a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry.
2007;68(6):843-53.
259. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy
and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second
multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol.
2008;28(2):156-65.
260. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, et al. A double-blind, placebocontrolled
study of aripiprazole adjunctive to antidepressant therapy among depressed
outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Psychother Psychosom. 2012;81(2):87-97.
261. Fabrazzo M, Perris F, Monteleone P, Esposito G, Catapano F, Maj M. Aripiprazole
augmentation strategy in clomipramine-resistant depressive patients: an open preliminary
study. Eur Neuropsychopharmacol. 2012;22(2):132-6.
262. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, et al. Olanzapine/
fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and
nortriptyline resistance. J Clin Psychiatry. 2005;66(10):1289-97.
263. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized,
double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in
treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-36.
264. Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, et al. An integrated
analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant
depression. J Clin Psychiatry. 2009;70(3):387-96.
265. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation
strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131-4.
266. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, et al. A randomized,
placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat
unipolar, non-psychotic major depression. J Psychiatr Res. 2009;43(3):205-14.
267. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, et al.
Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann
Intern Med. 2007;147(9):593-602.
268. Song ZW, Liu XB, Li YD. Venlafaxine combined with low-dose risperidone for treatmentresistant
depression. J Clin Rehab Tis Eng Res. 2007;11.
269. Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, et al. A pilot study of the efficacy and safety of
paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone
in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol.
2011;31(5):638-42.
270. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake
inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual
depressive symptoms: A randomized, placebo-controlled pilot study. Depress anxiety.
2007;24(7):487-94.
271. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised,
placebo-controlled studies of extended release quetiapine fumarate adjunctive to
Guía de Práctica Clínica sobre el manejo de la depresión en el adulto 253